SGLT2 Inhibitors for Heart Failure: A 2025 Overview

Written By Nicole Dellairo-Davidson, PA-C, MS

SGLT2 inhibitors improve outcomes across HFrEF, HFmrEF, and HFpEF populations, regardless of diabetes status. Major trials (DAPA-HF, EMPEROR-Reduced, DELIVER) show reduced HF hospitalization, improved symptoms, and renal protection. Guidelines place SGLT2i among foundational therapies. These agents are well tolerated, easy to initiate, and now widely used in 2025 clinical practice.

Full PDF click HERE

Nicole Dellairo-Davidson, PA-C, MS
Previous

“I Always Thought Something Was Wrong With Me”: A Patient’s Journey Through Adult ADHD
Next

Sarah’s Story: A Patient Journey Through Supraventricular Tachycardia (SVT)